biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM
Cullinan Therapeutics
Octagon Therapeutics is a biotech organization headquartered in Providence, USA. It trades on NYSE under ticker CGEM. Primary therapeutic focus areas include Advanced Solid Tumor, Sjogren's Disease, Acute Myeloid Leukemi
Dyer St, Providence, Rhode Island 02903, US HQ
2017 Founded
7 Employees
Public company Type
CGEM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dyer St, Providence, Rhode Island 02903, US
- Founded
- 2017
- Employees
- 7
- Programs
- 16
- Drugs
- 14
- Patents
- 3
CLN-049-002
Phase 1 · other · Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
CLN-049-002 for Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLN-049-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cullinan Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
- Status
- active
- Trials
- 1